AR044052A1 - Medicamentos para la terapia perioperatoria de dos etapas de tumores solidos - Google Patents
Medicamentos para la terapia perioperatoria de dos etapas de tumores solidosInfo
- Publication number
- AR044052A1 AR044052A1 ARP040101356A ARP040101356A AR044052A1 AR 044052 A1 AR044052 A1 AR 044052A1 AR P040101356 A ARP040101356 A AR P040101356A AR P040101356 A ARP040101356 A AR P040101356A AR 044052 A1 AR044052 A1 AR 044052A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- anticancer
- use according
- antibody
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 230000001093 anti-cancer Effects 0.000 abstract 4
- -1 biotin compound Chemical class 0.000 abstract 4
- 229960002685 biotin Drugs 0.000 abstract 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 3
- 235000020958 biotin Nutrition 0.000 abstract 3
- 239000011616 biotin Substances 0.000 abstract 3
- 108090001008 Avidin Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000010415 tropism Effects 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Empleo de un agente dotado de tropismo tumoral en combinación con otro agente con actividad anticancerígena y con afinidad con el primer agente, para la preparación de un medicamento útil para la terapia perioperatoria de dos etapas de tumores sólidos. La presente implica una mayor localización de su actividad anticancerígena, una reducción del número de etapas de administración y la posibilidad de reducir las dosis anticancerígenas, con una resultante disminución de los efectos laterales, pero sin perder su eficacia. Reivindicación 2: Empleo de acuerdo con la reivindicación 1, caracterizado porque dicho agente dotado de tropismo tumoral contiene uno o más anticuerpos específicos para antígenos asociados al tumor. Reivindicación 3: Empleo de acuerdo con la reivindicación 2, caracterizado porque el anticuerpo o los anticuerpos en dicho medicamento están biotinilados y combinados con un compuesto de avidina, y dicho segundo agente es un compuesto de biotina que contiene un agente anticancerígeno. Reivindicación 4 Empleo de acuerdo con la reivindicación 2, caracterizado porque el anticuerpo en dicho medicamento está avidinado y combinado con un compuesto de biotina que contiene un agente anticancerígeno. Reivindicación 6: Empleo de acuerdo con cualquiera de las reivindicaciones 2 a 5, caracterizado porque dicho anticuerpo es antitenascina. Reivindicación 8: Empleo de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizado porque dicho agente anticancerígeno se selecciona entre el grupo compuesto por radioisótopos, agentes quimioterápicos, toxinas y células anticancerosas. Reivindicación 9: Empleo de acuerdo con la reivindicación 8, caracterizado porque dicho radioisótopo se selecciona entre el grupo que comprende Fe-52, Mn-52m, Co-55, Cu-64, Ga-67, Ga-68, Tc-99m, In-111, I-123, I-125, I-131, P-32, Sc-47, Cu-67, Y-90, Pd-109, Ag-111, I-131, Pm-149, Re-186, Re-188, At-211, Pb-212, Bi-212, Lu-177. Reivindicación 25: Kit para la terapia sistemática y/o locorregional intraoperatoria y perioperatoria adyuvante de dos etapas, que contiene un conjunto de envases separados, donde el primer envase contiene un anticuerpo biotinilado específico para antígenos asociados a un tumor o una mezcla de anticuerpos, el segundo envase contiene un compuesto de avidina, el tercer envase contiene un compuesto de biotina que contiene un agente anticancerígeno, y opcionalmente un cuarto envase contiene albúmina biotinilada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000196A ITRM20030196A1 (it) | 2003-04-24 | 2003-04-24 | Uso di reagenti per la preparazione di un medicamento |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044052A1 true AR044052A1 (es) | 2005-08-24 |
Family
ID=29765781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101356A AR044052A1 (es) | 2003-04-24 | 2004-04-22 | Medicamentos para la terapia perioperatoria de dos etapas de tumores solidos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7935346B2 (es) |
| EP (1) | EP1615668B1 (es) |
| JP (1) | JP4949016B2 (es) |
| KR (1) | KR20060005383A (es) |
| CN (1) | CN1777446A (es) |
| AR (1) | AR044052A1 (es) |
| AU (1) | AU2004231377B2 (es) |
| BR (1) | BRPI0409604A (es) |
| CA (1) | CA2522580C (es) |
| CY (1) | CY1113488T1 (es) |
| DK (1) | DK1615668T3 (es) |
| ES (1) | ES2398389T3 (es) |
| HR (1) | HRP20121052T8 (es) |
| IT (1) | ITRM20030196A1 (es) |
| MX (1) | MXPA05011293A (es) |
| PL (1) | PL1615668T3 (es) |
| PT (1) | PT1615668E (es) |
| SI (1) | SI1615668T1 (es) |
| TW (1) | TWI368518B (es) |
| WO (1) | WO2004093916A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| LT2185203T (lt) * | 2007-08-02 | 2017-06-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oksiduotas avidinas, pasižymintis ilga egzistavimo gydytuose audiniuose trukme |
| IT1398977B1 (it) | 2009-06-25 | 2013-03-28 | Icgeb | Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1 |
| CA2842276C (en) * | 2011-08-02 | 2020-11-24 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical composition of oxidised avidin suitable for inhalation |
| US20160331853A1 (en) * | 2014-01-21 | 2016-11-17 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
| US10925852B2 (en) * | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| IT1245748B (it) * | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| CA2178476A1 (en) | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| US20030003051A1 (en) | 2001-06-11 | 2003-01-02 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
| ITRM20020071A1 (it) | 2002-02-11 | 2003-08-11 | Sigma Tau Ind Farmaceuti | Contenitore per flacone di radiofarmaco, e corredo per la sua infusione in un paziente o per il suo trasferimento altrove. |
| US20030228256A1 (en) | 2002-06-11 | 2003-12-11 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2003
- 2003-04-24 IT IT000196A patent/ITRM20030196A1/it unknown
-
2004
- 2004-04-07 CN CNA200480010867XA patent/CN1777446A/zh active Pending
- 2004-04-07 CA CA2522580A patent/CA2522580C/en not_active Expired - Fee Related
- 2004-04-07 DK DK04726249.8T patent/DK1615668T3/da active
- 2004-04-07 AU AU2004231377A patent/AU2004231377B2/en not_active Ceased
- 2004-04-07 BR BRPI0409604-5A patent/BRPI0409604A/pt not_active IP Right Cessation
- 2004-04-07 JP JP2006507647A patent/JP4949016B2/ja not_active Expired - Fee Related
- 2004-04-07 PL PL04726249T patent/PL1615668T3/pl unknown
- 2004-04-07 MX MXPA05011293A patent/MXPA05011293A/es active IP Right Grant
- 2004-04-07 PT PT47262498T patent/PT1615668E/pt unknown
- 2004-04-07 EP EP04726249A patent/EP1615668B1/en not_active Expired - Lifetime
- 2004-04-07 SI SI200431974T patent/SI1615668T1/sl unknown
- 2004-04-07 US US10/554,410 patent/US7935346B2/en not_active Expired - Fee Related
- 2004-04-07 WO PCT/IT2004/000184 patent/WO2004093916A1/en not_active Ceased
- 2004-04-07 HR HRP20121052TT patent/HRP20121052T8/hr unknown
- 2004-04-07 ES ES04726249T patent/ES2398389T3/es not_active Expired - Lifetime
- 2004-04-07 KR KR1020057019995A patent/KR20060005383A/ko not_active Ceased
- 2004-04-12 TW TW093110125A patent/TWI368518B/zh not_active IP Right Cessation
- 2004-04-22 AR ARP040101356A patent/AR044052A1/es not_active Application Discontinuation
-
2012
- 2012-12-14 CY CY20121101221T patent/CY1113488T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1615668A1 (en) | 2006-01-18 |
| AU2004231377A1 (en) | 2004-11-04 |
| DK1615668T3 (da) | 2013-02-04 |
| CA2522580C (en) | 2013-08-06 |
| TW200501984A (en) | 2005-01-16 |
| SI1615668T1 (sl) | 2013-01-31 |
| WO2004093916A1 (en) | 2004-11-04 |
| US20060251579A1 (en) | 2006-11-09 |
| MXPA05011293A (es) | 2006-01-24 |
| PL1615668T3 (pl) | 2013-03-29 |
| AU2004231377B2 (en) | 2010-08-05 |
| CN1777446A (zh) | 2006-05-24 |
| JP4949016B2 (ja) | 2012-06-06 |
| CY1113488T1 (el) | 2016-06-22 |
| ES2398389T3 (es) | 2013-03-15 |
| KR20060005383A (ko) | 2006-01-17 |
| PT1615668E (pt) | 2013-01-14 |
| WO2004093916A8 (en) | 2005-11-03 |
| BRPI0409604A (pt) | 2006-04-18 |
| US7935346B2 (en) | 2011-05-03 |
| ITRM20030196A0 (it) | 2003-04-24 |
| EP1615668B1 (en) | 2012-12-05 |
| ITRM20030196A1 (it) | 2004-10-25 |
| JP2006524235A (ja) | 2006-10-26 |
| HRP20121052T8 (en) | 2013-03-31 |
| TWI368518B (en) | 2012-07-21 |
| HRP20121052T1 (hr) | 2013-01-31 |
| CA2522580A1 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0496074B1 (en) | Biotinylated monoclonal antibodies, avidin and biotin for diagnosis and therapy | |
| US5630996A (en) | Two-step pretargeting methods using improved biotin-active agent conjugates | |
| Goodwin et al. | Advances in pretargeting biotechnology | |
| FI3682907T3 (fi) | Radiomerkityn nanoaineen käyttö syövän prognoosissa ja diagnoosissa | |
| BRPI0411986A (pt) | forma de dosagem farmacêutica multiparticulada, contendo substáncias peptìdicas ou protéicas ativas formuladas de maneira mucoadesiva, e um método para produzir a dita forma de dosagem farmacêutica | |
| Rusckowski et al. | Pretargeting using peptide nucleic acid | |
| AR044052A1 (es) | Medicamentos para la terapia perioperatoria de dos etapas de tumores solidos | |
| US5955605A (en) | Biotinidase resistant biotin-DOTA conjugates | |
| Frampas et al. | Improvement of radioimmunotherapy using pretargeting | |
| WO1995015770A1 (en) | Pretargeting methods and compounds | |
| US6287536B1 (en) | Two-step pretargeting methods using improved bidtin-active agent conjugates | |
| WO2003101496A1 (en) | Methods and compositions for intravesical therapy of bladder cancer | |
| CN101772353B (zh) | 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白 | |
| CZ186996A3 (en) | Method of selective provocation of methionine insufficiency for malignant cells of mammals | |
| JP2006524235A5 (es) | ||
| JP2010535166A5 (es) | ||
| WO2004054615A1 (en) | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent | |
| JP2005532343A (ja) | 脳およびｃｎｓ腫瘍の放射免疫治療のための方法および組成物 | |
| KR102649965B1 (ko) | 갑상선 수질암 표적용 조성물 | |
| van Schaijk | Pretargeted Radioimmunotargeting with Bispecific anti-tumor x anti-DTPA (In) Antibodies. | |
| Goyal et al. | Nanotechnology: A novel approach towards cancer treatment | |
| Epenetos | Konstantinos N. Syrigos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |